. Erythropoietin protects tubular basement membrane by promoting bone marrow to release extracellular vesicles containing tPAtargeting miR-144.
renal fibrosis; tubular basement membrane; EPO; extracellular vesicle; miRNA ERYTHROPOIETIN (EPO) IS A hormone produced by kidneys and promotes the formation of red blood cells by stimulating bone marrow. For end-stage kidney disease (ESRD) patients, EPO has been widely used in clinical settings to relieve the anemia resulted from the lack of production of EPO by disabled kidneys. In recent years, EPO has also been reported to play a role in attenuating the progression of renal tubulointerstitial fibrosis (11, 19) . However, the mechanism underlying the protective effect of EPO remains unknown.
Renal fibrosis is an inevitable outcome of nearly all kinds of chronic kidney disease (CKD) although the mechanism that promotes the progression of renal injury is incompletely understood (32, 34) . Disruption of the integrity of the tubular basement membrane (TBM) has been widely regarded as a key factor contributing to renal tubulointerstitial fibrosis (15, 32, 33) . Tissue plasminogen activator (tPA), a major component in the proteolytic network, is upregulated in the diseased kidney and promotes the disruption of renal TBM via activating matrix metalloproteinase 9 (MMP9). Knockout of tPA or MMP9 displays a protection for the integrity of TBM in obstructed mice kidneys (30, 33) .
MicroRNAs (miRNAs), a family of ϳ22-nt noncoding RNAs, is responsible for regulating the expressions of up to 30% of mammalian genes. Accumulating evidences suggest that miRNAs modulate the expression level and activity of many molecules that are involved in the renal fibrosis process (1, 4, 14) , providing a novel miRNA-based mechanism of renal tubulointerstitial fibrosis regulation. Recently, antidoping studies showed that plasma miRNA-144 (miR-144) was markedly upregulated by EPO (13, 25) . A significant upregulation of plasma miR-144 could be induced by only a single dose of EPO, and a high level of miR-144 induced by EPO could last for as long as 1 mo (13) . Bioinformatics analysis has indicated that miR-144 can target the 3=-untranslated region (UTR) of tPA. Under physiological conditions, upregulated miR-144 might be beneficial for erythroid homeostasis (24) . Extracellular vesicles (EVs) are fragments of plasma membrane shed from almost all cell types. EVs play a role in intercellular communication and can transport mRNA, microRNA, and protein between various cells. Both proteins and RNAs are susceptible to enzymatic degradation; however, once carried by EVs, proteins and RNAs can be safely transported into target cells across various distances. It was therefore hypothesized that the upregulated plasma miR-144 by EPO was probably encapsulated in EVs to play biological effects.
In the present study, employing a mouse model of renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction (UUO), we demonstrated that administration of EPO markedly attenuated the disruption of TBM by the UUO procedure. EPO treatment attenuated the activation of tPA and MMP9, the major matrix proteolytic network in the obstructed kidney. The protective effect of EPO on the integrity of mouse TBM was largely inhibited by depleting miR-144. Instead of acting directly on the kidney, EPO strongly increased the level of circulating miR-144, which was delivered by EVs to the injured renal fibroblasts, in which miR-144 targeted the 3=-UTR of tPA and suppressed tPA expression. The effect of EPO on stimulating bone marrow cell releasing miR-144-containing EVs to inhibit tPA expression and suppress the level and activity of MMP9 in renal fibroblasts has further confirmed in vitro study results using primarily bone marrow-derived Sca-1 ϩ CD44 ϩ
CD11b
Ϫ CD19 Ϫ cells and renal fibroblasts.
MATERIALS AND METHODS
Animal models. Male CD-1 mice, weighing 18 -20 g, were purchased from the Shanghai experimental animal center (Shanghai, China). They were housed in the animal facilities of the experimental animal center of Nanjing Medical University with free access to food and water. Animals were treated humanely in accordance with National Medical Advisory Committee (NMAC) guidelines and by use of approved procedures of the institutional animal care and use committee at the Nanjing Medical University (Nanjing, China). We followed the ARRIVE guidelines when reporting in vivo experiments in animal research. There were at least six mice in each group in this study. Renal tubulointerstitial fibrosis was induced by UUO. UUO was performed using an established procedure (32) . Briefly, under general anesthesia, the left ureter was double-ligated using 4-0 silk after a midline abdominal incision. Mice in the sham group had their ureter exposed and manipulated but not ligated. Mice were euthanized at different time points as indicated after surgery, and the obstructive kidneys were removed for further investigation. Recombined human EPO (rhuEPO, S20050090, Hayao Biotechnology) was administered intraperitoneally at a dose of 1,000 U/kg body wt three times a week and started from 1 wk before the UUO surgery (13) . A total of 150 nM phosphorothioate-modified antagomir-144 or scrambled oligonucleotide (both from GenePharma) was administered to each mouse by a single intravenously injection 1 day before UUO. Mutant lentivirus, in which miR-144 was encapsulated (LV-miR-144), was administered through tail vein injection. A total of ϳ2 ϫ 10 8 TU lentivirus was given on three separated days before UUO. Control mice were administered the same amount of lentivirus encapsulating negative control oligonucleotide (LV-N.C.). Lentiviruses (both from GenePharma) were green fluorescent protein (GFP) labeled.
Fibroblast cell culture and treatment. The rat renal fibroblast cell line (NRK-49F) was purchased from the cell resource center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, which was originally obtained from American Type Culture Collection (ATCC; CRL-1570TM). Cells were cultured in DMEM-F12 supplemented with 10% FBS (Invitrogen Life Technologies). For transforming growth factor (TGF)-␤1 treatment, NRK-49F cells were seeded at 80% confluence in complete medium containing 10% FBS. Twenty-four hours later, the cells were changed to serum-free medium and incubated for 16 h. Cells were treated with recombined human TGF-␤1 (rhTGF-␤1; R&D Systems) at a dose of 5 ng/ml. For transfection, an miR-144 mimic or miR-144 inhibitor (Qiagen) was transfected using Lipofectamine 2000 (Invitrogen) according to the protocol provided by the manufacturer.
Primary bone marrow-derived cell culture and treatment. Mice were euthanized, and bone marrow was isolated by flushing the femur and tibia with RPMI-1640 media (31800-022, Invitrogen) using sterile syringes with a 0.6 ϫ 25-mm needle. Cells were cultured in RPMI-1640 media supplemented with 10% FBS (Invitrogen). Cells surface markers were identified after cultured for 1 wk by flow cytometry as previously reported (3). Antibodies and reagents were obtained from sources as follows: CD-44-PE (5140414404), CD-Sca-1-PE (5140722440), CD-11b-FITC (5140513446), CD-19-FITC (5140513514), mouse IgG2a-PE (5140527119), rat IgG1-PE (5140722401), rat IgG2a-PE (5140722407), rat IgG2b-PE (5140722422), rat IgG2a-FITC (5140722406), rat IgG2b-FITC (5140722405), and FcR blocking reagent (5140722461). Cells were treated with 10 U/ml of EPO for various time points as indicated. Cells and their culture media were collected for further investigations.
Plasma collection and RNA isolation. Plasma samples were collected at different time points as indicated. An equal volume of 100 l plasma from each group was applied for total RNA isolation, and acidic phenol was used, followed by chloroform/isopropanol purification. The total RNA was then applied for reverse transcription to create a plasma miRNA cDNA library, using an miScript II RT kit (Qiagen).
EV isolation and administration. Plasma EVs were isolated by differential centrifugation according to previous publications (35) . Briefly, plasma were centrifuged as follows: after the removal of cells and other debris by centrifugation at 300, 1,200, and 10,000 g for 5, 20, and 30 min, respectively, the supernatant was centrifuged at 110,000 g for 1 h (all steps were performed at 4°C). EVs from cell culture media were isolated using a PureExo exosome isolation kit (P100) according to instructions by the manufacture. EVs were resuspended in FBS-free media. Total RNA of EVs was extracted using TRIzol LS reagent (Invitrogen) to examine the miR-144 level. For normalization, the protein concentration of isolated EVs was examined. Total RNA was extracted from the EV fraction with the protein amount of 1 mg. Isolated EVs were resuspended, administered through tail vein injection, or applied to incubate cultured NRK-49F cells. For cell culture, 10 6 fibroblasts were incubated with EVs isolated from a total of 100 or 200 l of plasma or 10 6 cultured bone marrow-derived cells (BMDCs). For tail vein injection, each mouse was injected with EVs isolated from a total of 600 l plasma or 10 7 BMDCs.
Fluorescence labeling of EVs. Before centrifugation at 110,000 g, plasma was prelabeled with or without DiI-C18 (Molecular Probes) and then centrifuged to isolate EVs. Fluorescent-labeled EVs were resuspended, administered through the tail vein, or applied to incubate cultured NRK-49F cells as mentioned above. Kidneys were harvested 12 h later after EV administration. The frozen tissues were optimum cutting temperature compound (OCT)-embedded and sectioned at 5 m in thickness. NRK-49F cells were washed and fixed after incubation for 12 h. Tissues and cells were immediately observed under a Nikon Eclipse 80i Epi-fluorescence microscope equipped with a digital camera (DS-Ri1, Nikon). In each experimental setting, immunofluorescent images were captured with identical exposure settings.
Transmission electron microscopy. For conventional transmission electron microscopy (TEM), the EV pellet isolated from plasma was placed in a droplet of 2.5% glutaraldehyde in PBS buffer and fixed. Samples were rinsed and postfixed in 1% osmium tetroxide. The samples were then embedded in 10% gelatin, fixed, and cut into several blocks (Ͻ1 mm 3 ). The samples were dehydrated in increasing concentrations of alcohol and infiltrated with increasing concentrations of Quetol-812 epoxy resin mixed with propylene oxide. Samples were embedded in pure, fresh Quetol-812 epoxy resin and polymerized. Ultrathin sections (100 nm) were cut using a Leica UC6 ultramicrotome and poststained with uranyl acetate for 10 min and with lead citrate for 5 min at room temperature before observation in a FEI Tecnai T20 transmission electron microscope, operated at 120 kV.
miRNA in situ hybridization. miRNA in situ hybridization (ISH) was performed using a mercury LNATM microRNA ISH optimization kit (Exiqon) for formalin-fixed, paraffin-embedded kidney samples according to the protocol by the manufacturer. Briefly, 10-mthick sections were prepared, followed by deparaffinization in xylene and ethanol. The slides were incubated with 15 mg/ml of proteinases-K (Exiqon) for 20 min at 37°C. After being washed and dehydrated, the slides were hybridized with a double-DIG-labeled, LNATM miR-144 probe, LNATM scrambled miRNA probe,
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EPO PROMOTES tPA-TARGETING miR-144 SECRETION LNATM U6 snRNA probe, or LNATM miR-126 probe (positive control, Exiqon) for 1 h at 55°C. The slides were washed with SSC buffer and then incubated with blocking solution for 15 min, followed by incubation with anti-DIG reagent for 60 min, AP substrate for 2 h at 30°C, and KTBT buffer for 2 ϫ 5 min. The slides were mounted with mounting medium, and results were analyzed by light microscopy (Nikon Eclipse 80i).
Quantitative PCR analysis of pre-miRNA and mature miRNA. Quantitative PCR (Q-PCR) was performed using an Applied Biosystems 7300 Sequence Detection system. Total RNA of cells or tissues was prepared using a TRIzol isolation system according to instructions by the manufacturer (Invitrogen). For the pre-miRNA and mature miRNA cDNA library, the first strand of cDNA was synthesized using 1 g of RNA in 20 l of reaction buffer using miScript RT II buffer (Qiagen). The mix was incubated at 37°C for 60 min, followed with 95°C for 5 min. Subsequently, real-time quantification was performed using an Applied Biosystems 7300 sequence detection system. The 20-l PCR reaction system consisted of 1 l RT product, 2 l 10ϫ miScript universal primer, 2 l 10ϫ miScript primer assay, 10 l 2ϫ QuantiTect SYBR green PCR Master Mix, and RNase-free water (Qiagen). The mixtures were incubated at 95°C for 15 min, followed by 40 cycles of 94°C for 15 s, 55°C for 30 s, and 70°C for 34 s. All reactions were run in triplicate. The CT data was determined using default threshold settings, and the mean CT was calculated from the triplicate PCRs. The ratio of miRNAs was calculated by using the 2 Ϫ⌬CT equation, in which ⌬CT ϭ CTtreatment Ϫ CTsham/control. All primers (pre-miR-144, miR-144, and U6) were purchased from Qiagen. U6 was used for normalization in miRNA qPCR when RNA was extracted from cell or tissue samples.
Immunofluorescent staining. Indirect immunofluorescent staining was performed according to an established procedure (32) . Briefly, kidney sections were washed twice with cold PBS and fixed with cold methanol/acetone (1:1) for 10 min at Ϫ20°C. Following three extensive washings with PBS, the sections were blocked with 0.1% Triton X-100 and 2% normal donkey serum in PBS buffer for 40 min at room temperature and then incubated with the mouse anti-laminin antibodies (L9393, Sigma-Aldrich, St. Louis, MO), followed by staining with TRITC-conjugated secondary antibody. Cells were double stained with 4,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei. Slides were viewed with a Nikon Eclipse 80i Epi-fluorescence microscope equipped with a digital camera (DS-Ri1, Nikon). In each experimental setting, immunofluorescence images were captured with identical exposure settings.
Western blot analysis. Samples were lysed with SDS sample buffer. The supernatants were collected after centrifugation at 13,000 g at 4°C for 20 min. Protein concentration was determined using a BCA protein assay kit (Sigma), and lysates were mixed with an equal amount of 2ϫ SDS loading buffer. Samples were heated at 100°C for ϳ5-10 min before loading and were separated on precast 10 or 5% SDS-polyacrylamide gels (Bio-Rad). Samples with 50 g protein were loaded in each lane. Detection of protein expression by Western blotting was carried out according to the established protocols described previously (32) . The primary antibodies were anti-tPA (PA63, mouse, Oxford Biomedical Research) and anti-CD63 (sc-15363, rabbit), anti-tubulin (sc-53646, mouse), and anti-actin (sc-1616, goat) from Santa Cruz Biotechnology (Santa Cruz, CA). Quantification was performed by measurement of the intensity of the signals with the use of National Institutes of Health Image analysis software.
Gelatin zymographic analysis. Zymographic analysis of the MMP proteolytic activity in the cell culture media or kidney tissue homogenates was performed according to the method previously described (32) . Briefly, after different treatments as indicated, cell culture media were collected and centrifuged at 13,000 g for 5 min to remove cell debris. The protein concentration was determined using a BCA protein assay kit (Sigma). Kidney tissue homogenates were prepared essentially according to the methods previously described (32) . A constant amount of protein from the cell culture media (15 g) or kidney tissue homogenates (30 g) was loaded into 10% SDSpolyacrylamide gel containing 1 mg/ml gelatin (Bio-Rad). After electrophoresis, SDS was removed from the gel by incubation in 2.5% Triton X-100 at room temperature for 30 min with gentle shaking. The gel was washed well with distilled water to remove detergent and incubated at 37°C for 6 -48 h in a developing buffer containing 50 mM Tris·HCl, pH 7.6, 200 mM NaCl, 5 mM CaCl2, and 0.02% Brij 35. The gel was then stained with a solution of 30% methanol, 10% glacial acetic acid, and 0.5% Coomassie blue G250, followed by destaining in the same solution without dye. Proteinase activity was detected as unstained bands on a blue background representing areas of gelatin digestion. Two bands at the molecular mass of 92 and 72 kDa represented MMP9 and MMP2, respectively.
Morphological assessment. Kidney tissues were immersed in 4% neutral-buffered formaldehyde at 4°C for 48 h. The tissues were paraffin-embedded, processed for light microscopy, and sectioned at 3 m in thickness. Sections were then stained with hematoxylin-eosin (HE) for general histology and Masson for extra cellular matrix deposition. Pictures were taken with a Nikon Eclipse 80i microscope equipped with a digital camera (DS-Ri1, Nikon).
Immunohistochemical staining. Kidney sections (3 m) were deparaffinized and rehydrated by xylene, a graded alcohol series, and double deionized water. Briefly, after blocked with blocking buffer for 30 min at room temperature, sections were incubated with anticollagen I (sc-28657, Santa Cruz Biotechnology) or mouse anti-␣-SMA (A5691, Sigma-Aldrich), then with horseradish peroxidase (HRP)-conjugated secondary antibodies.
Luciferase assay. The plasmids of tPA 3=-UTR-wild-type, tPA 3= UTR-mutant, negative control, miR-144, and anti-miR-144 were constructed by Invitrogen. For miRNA plasmids, THE vector was pcDNA6.2-GW/EmGFP-miR (K4936-00, Life Technologies). For 3=-UTR plasmids, the vector was pmirGLO, and the length of inserted sequence was 207 base pairs containing wild-type or mutant tPA 3=-UTR. For a luciferase reporter assay, 2 g/ml of each plasmid was transfected into cells as indicated. At 24 h after transfection, luciferase activities were measured by a luciferase reporter assay system (E1980, Promega) and normalized to the negative control group.
Blood samples from patients administered or not administered EPO. The present study was approved by the Institutional Review Board of the Second Affiliated Hospital of Nanjing Medical University (Nanjing, China), and written informed consent was obtained from each participant. Blood samples (1-2 ml) were collected from 29 hemodialysis patients. Among them, 21 patients were administered with EPO (S20050090, Hayao Biotechnology) at a dose of 3,000 -9,000 U/wk. The other eight patients did not receive any EPO. Total RNA in 100 l plasma was extracted using TRIzol LS reagent (Invitrogen) to examine the miR-144 level.
Statistical analysis. Animals were randomly assigned to each group. Statistical analysis was performed using SigmaStat software (Jandel Scientific Software). Comparisons between groups were made using one-way ANOVA, followed by the t-test. P Ͻ 0.05 was considered significant. Data are presented as means Ϯ SE.
RESULTS

EPO protects the integrity of TBM in UUO mice.
To determine whether EPO protects the integrity of mouse TBM during renal tubulointerstitial fibrosis, we established a renal tubulointerstitial mouse model by UUO surgery (3, 6, 7) . rhuEPO was administered intraperitoneally at a dose of 1,000 U/kg body wt 1 wk before the UUO surgery. As shown in Fig. 1A , EPO attenuated extracellular matrix accumulation and renal fibrosis. Immunofluorescence staining of TBM composition protein laminin showed that TBM, normally forming continuous smooth lines surrounding renal tubules, was significantly disrupted after ureteral ob-F29 EPO PROMOTES tPA-TARGETING miR-144 SECRETION struction, especially on day 3 after UUO (Fig. 1B, arrows) . However, administration of EPO largely attenuated obstruction-induced disruption of TBM. With prolonged obstruction by UUO to 7 days, the structure of tubulointerstitial space was largely destroyed, as shown by tubular atrophy, interstitial dilatation, and TBM distortion. As tPA was reported to be detrimental in renal fibrosis by inducing MMP9, whose activation led to proteolysis of TBM (7, 12, 15, 33), we examined tPA expression, as well as MMP9 level and activity in mouse kidneys by Western blotting and gelatin zymography analysis, respectively. As shown in Fig.  1C , the expression of tPA was markedly increased on day 3 after UUO, which was in accordance with the disruption of mouse TBM. However, the upregulation of tPA in obstructed mouse kidneys was greatly abolished by EPO treatment. In line with this, the activation and level of MMP9 in obstructed mouse kidneys were also markedly inhibited by EPO (Fig. 1D) . Together, these results suggest EPO protects the integrity of TBM by upregulating miR-144 in mouse kidneys. It was previously reported that injection of EPO could upregulate the miR-144 level in blood cells (13, 25) . Moreover, miR-144 may serve as an inhibitor for tPA. We therefore postulated that the protective effect of EPO on TBM is through increasing the level of miR-144, which in turn, suppresses the expression of tPA. As shown in Fig. 2A , the miR-144 level in mouse kidneys was indeed increased following EPO injection. ISH further indicated that miR-144 was EPO PROMOTES tPA-TARGETING miR-144 SECRETION rarely expressed in mouse kidney tissues under normal conditions (Fig. 2B, left) . However, miR-144 was upregulated by EPO administration, and the EPO-induced miR-144 was mainly located in the renal tubulointerstitial region (Fig. 2B,  right, arrows) . To determine whether miR-144 protects the integrity of TBM, mice were administered miR-144-expressing lentivirus (LV-miR-144) through tail vein injection and then underwent the same UUO procedure. Control mice were administered lentivirus-expressing control oligonucleotide (LV-N.C.). As shown in Fig. 2C , GFP-labeled lentivirus (green) was detectable in mouse kidneys after intravenous injection. Q-PCR analysis showed that the level of miR-144 in mouse kidneys was increased 2.5-fold by LV-miR-144 compared with that by LV-N.C. (Fig. 2D) . Immunofluorescence labeling of laminin showed that the injection of either LV-miR-144 or LV-N.C. alone had no apparent effect on TBM morphology in control mice (data not shown); however, the integrity of TBM in mice injected with LV-N.C. was significantly disrupted on day 3 after UUO ( Fig. 2E, left, arrows) . In contrast, administration of LV-miR-144 markedly attenuated the TBM disruption caused by UUO (Fig. 2E, middle) . In agreement with this, injection of LV-miR-144 or LV-N.C. alone did not affect the level of tPA in normal mouse kidneys (Fig. 2F) . LV-N.C. showed no inhibition on induction of renal tPA by UUO, which was in accordance with the disruption of mouse TBM. However, LV-miR-144 significantly reduced the increase in the mouse renal tPA level induced by UUO (Fig. 2F, top) . Consistent with this, activation of MMP9 in obstructed mouse kidneys was markedly inhibited by LV-miR-144 (Fig. 2G,  top) . To further verify that EPO protected the integrity of TBM by increasing miR-144, we used miR-144 antagomir (antagomir-144) to deplete miR-144. EPO was administered as previously described. A total of 150 nM of phosphorothioatemodified antagomir-144 was administered to each mouse by a single intravenous injection 1 day before UUO. Immunofluorescence staining of renal tissue laminin showed that the protective effect of EPO on the integrity of TBM was eliminated by antagomir-144 (Fig. 2E, right, arrows) . Compared with scrambled control oligonucleotide (Scramble), expression of tPA (Fig. 2F, middle) was markedly increased by antagomir-144. Consistent with this, MMP9 activity was markedly increased by antagomir-144 (Fig. 2G, middle) . These results collectively suggest that upregulated miR-144 in the kidney by EPO protected the integrity of TBM after UUO.
miR-144-containing EVs protect the integrity of TBM in UUO mice. To our surprise, Q-PCR analysis showed that the miR-144 level was actually decreased after renal obstruction (data not shown). As the major parenchymal cells in the tubulointerstitial region, as well as tubular cells and fibroblasts, showed no increased expression of pre-miR-144 by EPO stimulation (data not shown), which is supported by observation of no alteration of pre-miR-144 in the kidney following administration of EPO for 1 wk (Fig. 3A) , the increased level of miR-144 in the renal tubulointerstitial region might not be derived from the de novo synthesis of miR-144 by renal tubular cells and fibroblasts but from the direct transportation of mature miR-144. To test this hypothesis, we therefore isolated total RNA from human and mouse plasma to examine the level of miR-144 following EPO injection. As shown in Fig. 3B , EPO injection induced an approximately fourfold increase in miR-144 level in both human and mouse plasma, which was in agreement with previous reports that erythropoiesis-stimulating agents increased the level of miR-144 in peripheral blood (13, 25) . Given that cell-secreted EVs are a major carrier for circulating miRNAs (35), we next tested whether circulating miR-144 was mainly encapsulated by EVs. Electron microscopy of the pellet isolated from mouse plasma by ultracentrifugation showed the clusters of EVs of ϳ30 -200 nm in diameter, surrounded by a double-layer membrane (Fig. 3C, top) . Equal amounts of proteins from EVs were analyzed by Western blotting for EV-enriched protein CD63. As shown in Fig.  3C (bottom) , CD63 was abundantly expressed in EVs derived from human/mouse plasma. Quantitative PCR analysis indicated that the majority of circulating miR-144 in mouse plasma was stored in EV fractions (Fig. 3D) . Moreover, compared with the EVs from control mice without EPO treatment, the circulating EVs from mice administered EPO had 15-fold higher level of miR-144 (Fig. 3E) . These results suggested that the majority of circulating miR-144 is in EVs and its level is increased following EPO injection.
To determine whether EPO protected the integrity of mouse TBM through EV-delivery of miR-144 into the cells in the mouse renal tubulointerstitial region, circulating EVs were isolated from mice injected without (control EV) or with EPO (EPO EV) and injected into mice through the tail vein before UUO. As shown in Fig. 3F , DiI-C 18 -labeled EVs (red dots, arrows) were readily detected in mouse kidneys after being intravenously injected into mice. Q-PCR analysis showed that the level of miR-144 in mouse kidneys was increased twofold by EPO EVs compared with that by control EVs (Fig. 3G) . In contrast, the relative level of pre-miR-144 in mouse kidneys was not changed by EPO EVs (Fig. 3H) . ISH analysis showed that increased miR-144 by injection of EPO EVs was largely located in the tubulointerstitial region (Fig. 3I, right, brown) . These results collectively suggest that the increase in miR-144 level in mouse kidney particularly in the tubulointerstitial region following the injection of EVs is contributed by the delivery of EPO EVs, which contain a higher level of miR-144 compared with control EVs.
MiR-144-containing EVs could repress expression of profibrotic markers in obstructed kidneys as EPO (Fig. 1A) did. We next determined whether EPO EVs could protect the integrity of TBM in obstructed kidneys. In this experiment, control mice or mice with UUO were injected with control or EPO EVs. Although immunofluorescence labeling of laminin showed that the injection of either control EVs or EPO EVs alone had no apparent effect on TBM morphology in control mice by immunofluorescence labeling of laminin (data not shown), the integrity of TBM in mice injected with control EVs was significantly disrupted on day 3 after UUO (Fig. 3J, left,  arrows) . In contrast, administration of EPO EVs markedly attenuated the TBM disruption caused by UUO (Fig. 3J, right) . In agreement with this, injection of control EVs or EPO EVs alone did not affect the level of tPA in normal mouse kidneys (Fig. 3K) . Control EVs showed no inhibition on induction of renal tPA by UUO, which was in accordance with the disruption of mouse TBM. However, EPO EVs significantly reduced the increase in mouse renal tPA level induced by UUO (Fig.  3K) . Consistent with this, activation of MMP9 in obstructed mouse kidneys was markedly inhibited by EPO EVs (Fig. 3L) . These results collectively suggest that the protective effect of EPO on the integrity of mouse TBM during UUO is likely F32 EPO PROMOTES tPA-TARGETING miR-144 SECRETION through plasma miR-144-mediated inhibition of a proteolytic event mediated by tPA and MMP9.
EV-delivered mir-144 inhibits tPA expression and consequent MMP9 activation in fibroblasts.
The inhibitory effect of miR-144-containing EVs on tPA expression and MMP9 activation was further examined in the cell culture system. In this experiment, EVs were isolated from the plasma of mice with (EPO EV) or without (control EV) EPO treatment as previously described. As shown in Fig. 4A , DiI-C 18 -labeled EVs from mouse plasma were rapidly entered into NRK-49F fibroblasts (red dots, arrows). The qRT-PCR assay further showed that the miR-144 level in cultured fibroblasts was dose dependently increased by EPO EV treatment (Fig. 4B) . However, the expression of pre-miR-144 in cultured NRK-49F fibroblasts was not affected by EPO EVs (Fig. 4C) . These two results suggested that plasma miR-144 could be transported by circulating EVs into fibroblasts and the increase in miR-144 level in fibroblasts was delivered by EVs but not de novo synthesized in these cells. Compared with control EVs, EPO EVs inhibited tPA expression (Fig. 4D ) and MMP9 activity (Fig. 4E ) in fibroblasts in a dose-dependent manner. In cultured fibroblasts, tPA expression was further upregulated by TGF-␤1 stimulation; however, the upregulation was markedly abolished by EPO EVs (Fig. 4F) . As a consequence, the activation of MMP9 by TGF-␤1 in fibroblasts was markedly inhibited by EPO EVs (Fig. 4G) . Taken together, secreted miR-144 encapsulated by EVs could be efficiently delivered into cultured fibroblasts, in which it suppressed fibroblast tPA expression and consequent MMP9 activation.
BMDC-secreted miR-144-containing EVs protect the integrity of TBM in UUO mice.
As the major target of EPO, the bone marrow was likely the major source of miR-144-containing EVs in mouse plasma. We next tested whether EPO could stimulate the expression of miR-144 in bone marrow cellsecreted EVs. In this experiment, primary cultured BMDCs were used. Cell surface marker analysis by flow cytometer indicated that these BMDCs maintained myeloid lineage characteristics, over 95% of cultured BMDCs were CD11b and CD19 negative, and over 70% of the CD11b-and CD19-negative BMDCs were CD44 and Sca-1 positive. After being treated with 10 U/ml EPO for 24 h, relative levels of miR-144 (Fig. 5A ) and pre-miR-144 (Fig. 5B ) in primarily cultured BMDCs were increased two-and sevenfold, respectively. The elevation of pre-miR-144 in BMDCs following EPO treatment indicated that the mature miR-144 was de novo synthesized by BMDCs. Electron microscopy of the isolated EVs showed clusters of vesicles of ϳ50 nm in diameter surrounded by double-layer membrane (Fig. 5C, top) . EVs derived from equal amounts of BMDC cells were analyzed by Western blotting for CD63. As shown in Fig. 5C (bottom) , CD63 was abundantly expressed in EVs derived from control/EPO-treated BMDCs. Total RNA was isolated from EVs containing 1 mg of EV protein. As shown in Fig. 5D , the relative abundance of miR-144 level in BMDC-derived EVs was markedly upregulated following EPO treatment.
To determine whether BMDC-derived miR-144-containing EVs could protect the integrity of TBM, EVs were isolated from cell culture medium of primary cultured mouse BMDCs treated without (control EV) or with EPO (EPO EV) and then administered through tail vein injection before UUO. Q-PCR analysis showed that the miR-144 level in mouse kidneys was increased twofold by EPO EVs (Fig. 5E, left) . Consistent with the result that EPO treatment did not alter the level of mouse renal pre-miR-144, the relative abundance of pre-miR-144 in mouse kidneys was not changed by treatment with EPO EVs (Fig. 5E, right) . ISH analysis confirmed significantly more miR-144 in the tubulointerstitial region after EPO EV treatment (Fig. 5F, right, brown) . These results suggest that mouse BMDC-secreted miR-144 via EVs could be transported to the kidney through the circulation. Immunofluorescence staining of laminin in mouse kidney sections indicated that injection of either control EVs or EPO EVs did not affect TBM morphology in control mice without UUO (data not shown). Injection of control EVs showed no protection from the disruption of mouse renal TBM induced by UUO (Fig. 5G, arrows) . In contrast, administration of EPO EVs markedly attenuated the disruption of mouse renal TBM under the same kidney obstructive condition. We next determined the effects of BMDCs-derived miR-144-containing EVs (EPO EV) on tPA expression and MMP9 activation in obstructed kidneys. As shown in Fig. 5 , H and I, control or EPO EVs displayed no effect on tPA expression in control mice without UUO. In agreement with previous reports (33), UUO treatment significantly increased the level of renal tPA. Injection of control EVs showed no inhibitory effect on UUO-induced expression of renal tPA, which was in accordance with the disruption of TBM. In contrast, the upregulation of mouse renal tPA induced by UUO was greatly abolished by administration of EPO EVs. Furthermore, activation of MMP9 in obstructed mouse kidney was markedly inhibited by EPO EVs but not control EVs (Fig.  5, J and K) .
BMDC-derived miR-144-containing EVs inhibit tPA expression and MMP9 activation in fibroblasts.
The effects of miR-144-containing EVs derived from BMDCs on fibroblast tPA expression and MMP9 activation were further examined in vitro. In this experiment, control and EPO EVs were isolated from the cell culture media of BMDCs treated without or with EPO as described above and then incubated with culture fibroblasts for 24 h at 37°C. As shown in Fig. 6A , top, incubation of EPO EVs dose dependently increased the level of miR-144 in cultured fibroblasts. In contrast, the level of premiR-144 in cultured fibroblasts was not altered by EPO EVs (Fig. 6A, bottom) . Together, these results suggest that the increase in the miR-144 level in fibroblasts is not due to the de novo synthesis of miR-144 but direct transport of mature miR-144 from miR-144-containing EVs derived from EPOtreated BMDCs. Compared with control EVs, EPO EVs inhibited fibroblast tPA expression (Fig. 6B ) and MMP9 activity (Fig. 6C ) in a dose-dependent manner. The TGF-␤1-induced upregulation of tPA in cultured fibroblasts also was largely abolished by EPO EVs (Fig. 6D) . As a consequence, the activation of fibroblast MMP9 by TGF-␤1 was blocked by EPO EVs (Fig. 6E) .
miR-144 suppresses TGF-␤1-induced fibroblast tPA expression and MMP9 activity via targeting the tPA 3=-UTR. We next determined whether miR-144 can suppress TGF-␤1-induced fibroblast tPA expression and MMP9 activity via targeting of the tPA 3=-UTR. First, a luciferase report assay confirmed that the tPA 3=-UTR served as a target of miR-144 (Fig. 7A) . Luciferase activities in cultured fibroblasts were decreased and increased when cells transfected with miR-144 mimic and anti-miR-144, respectively. The effects of miR-144 on modu-F33 EPO PROMOTES tPA-TARGETING miR-144 SECRETION lating luciferase activity were completely abolished when the predicted miR-144-binding site on the tPA 3=-UTR was mutated. Second, the effect of miR-144 on tPA level and MMP9 activity was tested in fibroblasts. After transfected with miR-144 mimic or anti-miR-144 antisense (miR-144 inhibitor), miR-144 levels in fibroblasts were markedly increased or decreased, respectively (data not shown). Western blot and gelatin zymographic analysis showed that both tPA level (Fig.  7B ) and MMP9 activity (Fig. 7C) were reduced by overexpression of miR-144. The effects of miR-144 on TGF-␤1-induced tPA expression and MMP9 activity in fibroblasts were also determined. As shown in Fig. 7, D and E, the level of tPA and activity of MMP9 was enhanced by TGF-␤1; however, the effect of TGF-␤1 was markedly abolished by miR-144 over-F34 EPO PROMOTES tPA-TARGETING miR-144 SECRETION expression. In contrast, depleting miR-144 by transfection with anti-miR-144 antisense significantly increased the level of tPA (Fig. 7F) and activity of MMP9 (Fig. 7G ) in fibroblasts. The miR-144 inhibitor further increased tPA expression (Fig. 7H ) and MMP9 activity (Fig. 7I) in the TGF-␤1-treated fibroblasts.
DISCUSSION
As a widely used erythropoiesis-stimulating agent in CKD patients, EPO has recently been used as an antifibrotic agent (8, 11, 16, 17, 19, 20, 26, 28) . In this study, we reported that EPO could attenuate the disruption of TBM in obstructed kidneys by promoting bone marrow cells to release miR-144-containing EVs, which enter into renal cells, particularly fibroblasts, and suppress the expression of tPA. Given that disruption of renal TBM is a key step in the irreversible progression of tubulointerstitial fibrosis, and as a major component in the matrix proteolytic network tPA plays a central role in disrupting TBM via activating MMPs (30, 33), we postulated that the protection of EPO on tubulointerstitial fibrosis in the obstructed mouse kidney might be due to the inhibition of the tPA-induced matrix proteolytic network.
It has been well documented that tPA modulates MMP9 gene expression and protein secretion (30, 33) ; the regulation of tPA expression, however, is unknown. Our results showed that miR-144, the level of which was increased in mouse kidneys following EPO treatment, could suppress tPA expression. Both bioinformatics analysis and experimental validation demonstrated the 3=-UTR of tPA as a target of miR-144. Upregulation of miR-144 attenuated, while downregulation of miR-144 promoted, TGF-␤1-induced tPA expression and MMP9 activation in fibroblasts. However, the tPA mRNA level was not changed by miR-144 (data not shown), which suggested that miR-144 regulates tPA by blocking the translation but not degradation of tPA mRNA.
In agreement with previous reports that circulating miR-144 was upregulated in human from 1 wk after administration of EPO and the upregulation lasted for 1 mo (13, 25) , administration of EPO in mice for 1 wk also resulted in an upregulation of miR-144 in mouse plasma. These findings suggest that miR-144 may be involved in EPO-induced downregulation of tPA. Despite the upregulation of mature miR-144, pre-miR-144 in mouse kidneys, however, was not changed by EPO. These results suggest that the upregulated miR-144 in mouse kidneys was not derived from de novo synthesis by renal 
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EPO PROMOTES tPA-TARGETING miR-144 SECRETION tubulointerstitial cells under EPO stimulation, but probably directly from the circulation. This speculation is supported by the fact that renal fibroblasts in humans, mice, and rats do not express the heterodimeric EPO receptor that mediates EPO stimulation (31) . In addition, we found that under normal physiological conditions, the kidney and other parenchyma organs only express a low level of miR-144, and in the cell culture system, treatment with EPO did not affect miR-144 levels in tubular cells or fibroblasts (data not shown).
To determine whether EPO protected the integrity of TBM via miR-144, lentivirus-mediated transfer and expression of miR-144 (LV-miR-144) or antagomir-144 was applied. Upregulation of miR-144 by LV-miR-144 directly attenuated TBM disruption after UUO. Antagomir, a chemically engineered oligonucleotide, can specifically bind to the 3=-end of the UTR of an mRNA strand and thus block miRNA from binding to the same site and prevent the degradation of miRNA target genes. In this way, administration of antagomir may not affect the miRNA level but instead increase the synthesis of protein targeted by miRNA. In this study, since tPA is expressed mainly in fibroblasts, the limited number of fibroblasts in normal kidneys might explain why antagomir-144 did not markedly upregulate tPA protein expression in normal kidneys. However, in obstructed kidneys, antagomir-144 eliminated the protective effect of EPO on the integrity of TBM, which confirmed that EPO protected TBM through upregulation of tPA-targeting miR-144.
To avoid degradation, substantial amounts of extracellular miRNAs are enclosed in EVs or combined with RNA-binding proteins including HDL, argonaute 2, and nucleophosmin 1 (5). EV-packaged and HDL-binding miRNAs function as secreted signaling molecules to influence the expression of target genes in recipient cells (2, 5, 29) . In this study, debits of plasma isolated by ultracentrifugation were clusters of double-layer membrane vesicles of 30 -200 nm in diameter and abundantly expressed EV-enriched protein CD63, which were EVs. Total RNA was isolated from EVs with 1 mg protein to reflect the relative changes in miR-144 in the same numbers of EVs. The results indicated that the relative abundance of miR-144 in circulating EVs was markedly upregulated by EPO. Compared with a 4-fold increase in plasma, there was a 15-fold increase in miR-144 in plasma EVs, which suggested that miR-144 was enriched in EVs.
The bioactivity of circulating EVs was confirmed by fluorescent tracing and Q-PCR analysis. Before administered through tail vein injection or applied to incubate cultured fibroblasts, circulating EVs were marked by a fluorescent dye Dil-C18. Detection of Dil-C18-positive dots in both mouse kidney and cultured fibroblasts indicated that circulating EVs could be uptaken by renal cells and cultured fibroblasts. Up- regulation of the relative abundance of mature miR-144 stimulated by circulating EVs from mice administered with EPO (EPO EV) indicates that exogenous miR-144 could be transported by EVs into both mouse kidneys and cultured fibroblasts. The relative abundance of pre-miR-144 in mouse kidneys and cultured fibroblasts was still not changed by EPO EV. Without suspension, the exogenous miR-144 relieved the upregulation of tPA and activation of MMP-9 and therefore attenuated disruption of TBM in obstructed kidneys. In cultured fibroblasts, EV-transported exogenous miR-144 regulated tPA and MMP-9, which further relieved the upregulation of tPA and activation of MMP-9 induced by TGF-␤1. These results suggested that circulating miR-144 mediated the regulations of the tPA-induced matrix proteolytic network and integrity of TBM by EPO.
Since our results suggested that an increase in renal the miR-144 level induced by EPO treatment is likely delivered by circulating EVs, the next question was to determine the source of the EVs. As bone marrow is the major target of EPO, we postulated that bone marrow might be the major source for the increased number of circulating EVs in the presence of EPO. To test this hypothesis, we first isolated, cultured, and identified bone marrow cells. CD11b is expressed on the surface of many leukocytes, including monocytes, neutrophils, nature killer cells, granulocytes, and macrophages (10, 18) . CD19 is expressed on the surface of B-lymphocyte (6). CD11b and CD19 were hardly detected in our primarily cultured BMDCs (Ͻ10%); while a large number of CD11b-and CD19-negative cells were Sca-1 and CD44 positive. The profile of surface markers on BMDCs cultured for 1 wk indicated that they might be bone marrow mesenchymal stem cells (MSCs) (3) . The cell surface markers of mouse BMDCs are as complex as those in humans (3). In mouse MSCs, CD44 and Sca-1 are always positive (22, 27) and CD11b and CD19 are negative (3), while CD45, CD73, CD90, and CD105 are uncertain (9, 21, 22, 27) . Identification of these BMDCs needs further investigation. The following experiments were performed on BMDCs cultured for 1 wk. Next, we tested whether the primarily cultured BMDCs could secrete miR-144-containing EVs by EPO treatment. In contrast to mouse kidneys or renal tubulointerstitial cells, EPO-treated BMDCs displayed an upregulation of both premiR-144 and mature miR-144, suggesting an increase in de novo synthesis of miR-144 in BMDCs in response to EPO treatment. The level of miR-144 in BMDC-derived EVs was also increased by EPO stimulation in a time-dependent manner. These results suggest that BMDCs might be a major source of miR-144-containing EVs in the circulation. Like the plasma EVs, BMDC-derived EVs increased the level of miR-144 but not pre-miR-144 and suppressed tPA level and MMP9 activity in mouse kidneys or cultured fibroblasts. These results suggested that exogenous miR-144 derived from bone marrow mediated the protective effect of EPO on mouse renal TBM.
In conclusion, our study demonstrates for the first time that miR-144-containing EVs from bone marrow cells mediate the protective effects of EPO on the integrity of TBM in obstructed kidneys. In response to EPO, mouse bone marrow cells express more miR-144 and secrete it via EVs, which in turn, deliver miR-144 into injured kidneys. The exogenous miR-144 suppresses the activity of the proteolytic network via a decreasing tPA level, as well as MMP9 level and activity in renal fibroblasts. Our study provides the treatment of EPO, a hormone widely used in clinical settings, as a novel therapeutic strategy for renal fibrosis.
